|
This report is being submitted as part of remediation activities associated with capa # 643143, which is addressing mdr reporting guidance from fdas 1995 preamble, which ensures complaints related to corrections and recalls which were previously reported to fda under 21 cfr 806 are now reported as mdrs; this is not a new malfunction/event.This mdr related to the puerto rico manufacturing site has been assigned a medwatch number from the medtronic minimed northridge site, per variance 5.Currently it is unknown whether or not the device may have caused or contributed to the event as no product has been returned.No conclusion can be drawn at this time.We therefore consider this report complete to the best of our knowledge.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employees caused or contributed to the event described in the report.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
It was reported to medtronic minimed that the customer experienced hyperglycemia with a blood glucose value of 368 mg/dl while traveling by plane, which later reduced to 138 mg/dl after treatment with the insulin pump (subcutaneous insulin infusion).Blood glucose value at the time of the event was 368 mg/dl.The customer was treated with insulin pump (subcutaneous insulin infusion).The event involved product(s) mmt-1715k.Troubleshooting was performed, including verifying pump settings and advising the customer on potential contributing factors such as site issues, insulin quality, and tubing.No further patient complications were reported.No product return is required for mmt-1715k.
|